Please assess the completion status of the following clinical trial:

Trial Title: Selinexor in Advanced Liposarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥12 years of age~2. Body surface area (BSA) ≥ 1.2 m2~3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment~4. Must have measurable disease per RECIST v1.1 Response Criteria~5. Radiologic evidence of disease progression within 6 months prior to randomization. If the patient received other intervening therapy after documented disease progression, further disease progression must be documented after the completion of the intervening therapy~6. Must have had at least 2 prior lines of systemic therapy for liposarcoma (not to exceed 5 prior lines)~7. If patient received any previous systemic therapy, the last dose must have been ≥ 21 days prior to randomization (or ≥ 5 half-lives of that drug, whichever is shorter) with all clinically significant therapy-related toxicities having resolved to ≤ Grade 1~Exclusion Criteria:~1. Patients with pure well-differentiated liposarcoma (WDLS), myxoid/round cell or pleomorphic tumor histologic subtypes~2. Known active hepatitis B (HepB), hepatitis C (HepC) or human immunodeficiency virus (HIV) infection~3. Known central nervous system metastases

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 2 Double-blinded: Selinexor (Type: EXPERIMENTAL): Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until progressive disease (PD).
- Phase 3 Double-blinded: Selinexor (Type: EXPERIMENTAL): Participants received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD.
- Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor (Type: PLACEBO_COMPARATOR): Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.
- Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor (Type: PLACEBO_COMPARATOR): Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.

Based on this trial design, predict the completion outcome and termination type (if applicable).